Crossmark

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

Crossref DOI link: https://doi.org/10.1136/jitc-2021-003580

Published Online: 2021-12-10

Published Print: 2021-12

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Shah, Manish A https://orcid.org/0000-0002-6913-9655
Cunningham, David

Metges, Jean-Philippe

Van Cutsem, Eric

Wainberg, Zev

Elboudwarej, Emon

Lin, Kai-Wen

Turner, Scott

Zavodovskaya, Marianna

Inzunza, David

Liu, Jinfeng

Patterson, Scott D

Zhou, Jingzhu

He, Jing

Thai, Dung

Bhargava, Pankaj

Brachmann, Carrie Baker

Cantenacci, Daniel V T
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02864381 at ClinicalTrials.gov

Documents that mention this clinical trial

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
https://doi.org/10.1136/jitc-2021-003580
Funding

Funding for this research was provided by:

Gilead Sciences, Inc.
License Information

License valid from 2021-12-09

Document is current

Any future updates will be listed below